Price Alert

Ayala Pharmaceuticals Inc... (AYLA)

NASDAQ: AYLA · Real-Time Price · USD

0.53

-0.00 (-0.73%)

At close: Jan 18, 2023, 9:56 PM

Ayala Pharmaceuticals Statistics

Share Statistics

Ayala Pharmaceuticals has 0 shares outstanding. The number of shares has increased by 6.38% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	6.38%
Shares Change (QoQ)	1.08%
Owned by Institutions (%)	n/a
Shares Floating	6.9M
Failed to Deliver (FTD) Shares	69,092
FTD / Avg. Volume	136.7%

Short Selling Information

The latest short interest is 80.34K, so 0% of the outstanding shares have been sold short.

Short Interest	80.34K
Short % of Shares Out	n/a
Short % of Float	0.75%
Short Ratio (days to cover)	1.24

Valuation Ratios

The PE ratio is -0.16 and the forward PE ratio is null. Ayala Pharmaceuticals's PEG ratio is 0.

PE Ratio	-0.16
Forward PE	n/a
PS Ratio	8.93
Forward PS	n/a
PB Ratio	-5.62
P/FCF Ratio	-0.18
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ayala Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.42, with a Debt / Equity ratio of -1.59.

Current Ratio	0.42
Quick Ratio	0.42
Debt / Equity	-1.59
Debt / EBITDA	-0.05
Debt / FCF	-0.05
Interest Coverage	506.8

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$19.77K
Profits Per Employee	$-1.09M
Employee Count	35
Asset Turnover	0.15
Inventory Turnover	n/a

Taxes

Income Tax	584K
Effective Tax Rate	-1.56%

Stock Price Statistics

The stock price has increased by 5.24% in the last 52 weeks. The beta is 0, so Ayala Pharmaceuticals's price volatility has been lower than the market average.

Beta	0
52-Week Price Change	5.24%
50-Day Moving Average	0.53
200-Day Moving Average	1.37
Relative Strength Index (RSI)	50.56
Average Volume (20 Days)	50,544

Income Statement

In the last 12 months, Ayala Pharmaceuticals had revenue of 692K and earned -38.01M in profits. Earnings per share was -2.46.

Revenue	692K
Gross Profit	90K
Operating Income	-37.5M
Net Income	-38.01M
EBITDA	-37.5M
EBIT	-37.5M
Earnings Per Share (EPS)	-2.46

Full Income Statement

Balance Sheet

The company has 2.41M in cash and 1.75M in debt, giving a net cash position of 657K.

Cash & Cash Equivalents	2.41M
Total Debt	1.75M
Net Cash	657K
Retained Earnings	-149.15M
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -34.51M and capital expenditures -2K, giving a free cash flow of -34.51M.

Operating Cash Flow	-34.51M
Capital Expenditures	-2K
Free Cash Flow	-34.51M
FCF Per Share	-2.23

Full Cash Flow Statement

Margins

Gross margin is 13.01%, with operating and profit margins of -5419.51% and -5493.21%.

Gross Margin	13.01%
Operating Margin	-5419.51%
Pretax Margin	-5408.82%
Profit Margin	-5493.21%
EBITDA Margin	-5419.51%
EBIT Margin	-5419.51%
FCF Margin	-4987.28%

Dividends & Yields

AYLA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for AYLA.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a